Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome

Familial Cancer

Volumn 13, Issue 1, 2014, Pages 57-63

  Nieuwenhuis, Marry H ^a   Kets, C Marleen ^b   Murphy Ryan, Maureen ^c   Yntema, Helger G ^b   Evans, D Gareth ^d   Colas, Chrystelle ^e   Møller, Pal ^f   Hes, Frederik J ^g   Hodgson, Shirley V ^h   Olderode Berends, Maran J W ⁱ   Aretz, Stefan ^j   Heinimann, Karl ^k   Gómez García, Encarna B ^l   Douglas, Fiona ^m   Spigelman, Allan ^n,o,p   Timshel, Susanne ^q   Lindor, Noralane M ^r   Vasen, Hans F A ^a,g  

^a Netherlands Foundation for the Detection of Hereditary Tumors   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^d ST MARY S HOSPITAL   (United Kingdom)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^j UNIVERSITY HOSPITAL BONN   (Germany)

^k UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^l MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^m NEWCASTLE UNIVERSITY   (United Kingdom)

ⁿ ST VINCENT'S CLINIC   (Australia)

^o Hunter Family Cancer Service   (Australia)

^p St Vincent's Hereditary Cancer Service   (Australia)

^q HVIDOVRE HOSPITAL   (Denmark)

^r MAYO CLINIC   (United States)

more..

Author keywords

Multiple hamartoma syndrome; Neoplasms; PTEN phosphohydrolase

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CHILD; COLORECTAL CANCER; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; KAPLAN MEIER METHOD; KIDNEY CANCER; LHERMITTE DUCLOS DISEASE; LUNG CANCER; MACROCEPHALY; MAJOR CLINICAL STUDY; MALE; MALE BREAST CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MIDDLE AGED; MISSENSE MUTATION; NONSENSE MUTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PTEN HAMARTOMA TUMOR SYNDROME; SEX DIFFERENCE; SKIN CANCER; THYROID CANCER; YOUNG ADULT; CLINICAL TRIAL; CONGENITAL TUMOR; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HETEROZYGOTE; INFANT; MULTICENTER STUDY; NEOPLASM; SYNDROME; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HETEROZYGOTE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASMS; PTEN PHOSPHOHYDROLASE; SYNDROME; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84896739101     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-013-9674-3     Document Type: Article

References (21)

1. Eng C (2011) PTEN Hamartoma tumor syndrome (PHTS). In: Pagon RA, Bird TD, Dolan CR, Stephens K, (eds) GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2001 Nov 29 [updated 2011 Jul 21]
2. Lachlan KL, Lucassen AM, Bunyan D, Temple IK (2007) Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet 44:579-585 (Pubitemid 47441766)
3. Riegert-Johnson DL, Gleeson FC, Roberts M, Tholen K, Youngborg L, Bullock M, Boardman LA (2010) Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract 8:6
4. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C (2010) Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 18:400-407
5. Bonneau D, Longy M (2000) Mutations of the human PTEN gene. Hum Mut 16:109-122 (Pubitemid 30604900)
6. Zhang S, Yu D (2010) PI (3) king apart PTEN's role in cancer. Clin Cancer Res 16:4325-4330
7. Patnaik MM, Raza SS, Khambatta S, Stanich PP, Goetz MP (2010) Oncophenotypic review and clinical correlates of phosphatase and tensin homolog on chromosome 10 hamartoma tumor syndrome. J Clin Oncol 28:e767-e768
8. Wang H, Karikomi M, Naidu S, Rajmohan R, Caserta E, Chen HZ, Rawahneh M, Moffitt J, Stephens JA, Fernandez SA, Weinstein M, Wang D, Sadee W, La Perle K, Stromberg P, Rosol TJ, Eng C, Ostrowski MC, Leone G (2010) Allele-specific tumor spectrum in Pten knockin mice. Proc Natl Acad Sci USA 107:5142-5147
9. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, Richardson AL, Zhang J, Pandolfi PP (2010) Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 42:454-458
10. Tan MH, Mester J, Peterson C, Yang Y, Chen JL, Rybicki LA, Milas K, Pederson H, Remzi B, Orloff MS, Eng C (2011) A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 88:42-56
11. Hollander MC, Blumenthal GM, Dennis PA (2011) PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 11:289-301
12. http://globocan.iarc.fr/
13. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J (1998) Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58:2720-2723 (Pubitemid 28311897)
14. Nowak DA, Trost HA (2002) Lhermitte-Duclos disease (dysplastic cerebellar gangliocytoma): a malformation, hamartoma, or neoplasm? Acta Neurol Scand 105:137-145 (Pubitemid 34258952)
15. Lok C, Viseux V, Avril MF, Richard MA, Gondry-Jouet C, Deramond H, Desfossez-Tribout C, Courtade S, Delaunay M, Piette F, Legars D, Dreno B, Saïag P, Longy M, Lorette G, Laroche L, Caux F, Cancerology Group of the French Society of Dermatology (2005) Brain magnetic resonance imaging in patients with Cowden syndrome. Medicine (Baltimore) 84:129-136 (Pubitemid 40418641)
16. Laury AR, Bongiovanni M, Tille JC, Kozakewich H, Nosé V (2011) Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity. Thyroid 21:135-144
17. Orloff MS, Eng C (2008) Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 41:5387-5397
18. www.nccn.org, Clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian, version 1.2011
19. LoPicollo J, Ballas MS, Dennis PA (2007) PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development. Crit Rev Oncol Hematol 63:203-214 (Pubitemid 47126868)
20. Iacobas I, Burrows PE, Adams DM, Sutton VR, Hollier LH, Chintagumpala MM (2011) Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer 57:321-323
21. Zhou XP, Marsh DJ, Morrison CD, Chaudhury AR, Maxwell M, Reifenberger G, Eng C (2003) Germline inactivation of PTEN and dysregulation of the phophoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet 73:1191-1198 (Pubitemid 37414231)